Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide. Ivonescimab is a type of drug called a bispecific antibody. Antibodies are proteins that specifically recognize and bind to other types of proteins called antigens. Antibodies and antigens can work together to help the immune system fight cancer cells. Bispecific antibody, meaning it targets two different molecules at the same time. Ivo

Trial Details

NCT ID
NCT07057791
Phase
PHASE2
Sponsor
PrECOG, LLC.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Ivonescimab 10 mg/kg
  • Ivonescimab 20 mg/kg
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Morristown, New Jersey, United States|40.79677,-74.48154
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • The Bronx, New York, United States|40.84985,-73.86641

Key Eligibility Criteria

  • Selection Criteria:
  • Patients must have pathologically confirmed Extensive Stage Small Cell Lung Cancer (ES-SCLC).
  • No prior systemic therapy for the disease under study (ES-SCLC).
  • Patients must have measurable disease according to Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →